Bristol Myers Squibb to Build $2.3 Billion Campus in Houston
By Connor Hart
Bristol Myers Squibb will build a $2.3 billion manufacturing campus in Houston, aiming to accelerate the delivery of next-generation medicines to patients.
The investment marks a significant milestone toward Bristol Myers Squibb's commitment to spend $40 billion in the U.S. over the next five years to bolster research and development, technology and domestic manufacturing.
The company said Monday that the new 600,000-square-foot facility will be modular and multi-modal, allowing it to add and reconfigure manufacturing capacity as needed, as well as manufacture multiple types of medicines simultaneously.
The campus, at Generation Park in Houston, will create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come, according to Bristol Myers Squibb. The company also expects to create roughly 2,000 construction and other indirect jobs between 2027 and 2030 as the facility is built and brought online.
"This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation," Chief Executive Christopher Boerner said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 10, 2026 09:39 ET (13:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States